Turner Syndrome
Conditions
Brief summary
This study investigated the effect of growth hormone on the growth of infants and toddlers with Turner syndrome during 2 years of treatment with growth hormone. This was compared with the growth of infants and toddlers with Turner syndrome who did not receive any growth hormone treatment. The overall aim was to prevent the growth failure usually seen during this period. The study also looked at middle ear disease, hearing problems, and cognitive and behavioral development.
Interventions
DRUGSomatropin
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
9 Months to 4 Years
Healthy volunteers
No
Inclusion criteria
* Karyotype-proven Turner syndrome that included a documented abnormality of the short arm of an X chromosome. * At least 9 months of age and not greater than 4 years of age. * Normal values for age for hemoglobin, thyroid stimulating hormone (TSH) and urinalysis (office dipstick is adequate), performed prior to study entry. * If there was a known history of hypothyroidism, then adequate thyroid hormone replacement must have been taken for at least 6 months prior to study entry.
Exclusion criteria
* Current or previous treatment with any therapy that may have directly influenced growth, including growth hormone, growth hormone-releasing hormone, estrogens and anabolic steroids such as oxandrolone. This included previous completion of, or withdrawal from, this study or any other study investigating therapeutic uses of growth hormone or growth hormone-releasing hormone. * Chronic treatment with systemic glucocorticoids in supra-physiological doses. * Treatment with potential growth-influencing medications such as methylphenidate (Ritalin), pemoline (Cylert), and amphetamines, at, or within 3 months prior to, study entry. * Presence of any Y chromosome component in the karyotype if gonads were in situ. Subjects whose karyotype contained Y chromatin, but who had undergone gonadectomy, were eligible to enter the study. * Presence of any additional known autosomal abnormality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Height at the end of two years in the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Middle ear problems assessed every 4 months | — |
| Hearing problems assessed annually | — |
| Cognitive and behavioral development assessed annually | — |
Countries
United States
Outcome results
None listed